GMAB
Genmab·NASDAQ
--
--(--)
--
--(--)
6.19 / 10
Outperform
Analyst sentiment is overwhelmingly bullish with H.C. Wainwright maintaining a Buy rating and a price target cut only modestly to $39. Fund-flow data show a 7.92/10 score with positive trends across block, small, large, and extra-large orders; only the medium category shows a mild negative tilt. This combination of strong institutional conviction and consistent capital inflows reinforces the positive outlook, aligning with the stock's overall Outperform rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionHC Wainwright & Co.
Times predicted7
Historical Win Rate42.9%
What is the analyst consensus for GMAB?
- GMAB holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.19/10 (Outperform).
